Inovio Pharmaceuticals Current Valuation vs. Cash Per Share

INO Stock  USD 4.07  0.01  0.25%   
Based on Inovio Pharmaceuticals' profitability indicators, Inovio Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Inovio Pharmaceuticals' ability to earn profits and add value for shareholders. At this time, Inovio Pharmaceuticals' Days Sales Outstanding is very stable compared to the past year. As of the 24th of November 2024, Sales General And Administrative To Revenue is likely to grow to 60.05, while Price To Sales Ratio is likely to drop 154.95. At this time, Inovio Pharmaceuticals' Total Other Income Expense Net is very stable compared to the past year. As of the 24th of November 2024, Interest Income is likely to grow to about 8.6 M, though Accumulated Other Comprehensive Income is likely to grow to (629.5 K).
For Inovio Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Inovio Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Inovio Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Inovio Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Inovio Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.43)
Revenue Per Share
0.025
Quarterly Revenue Growth
(0.55)
Return On Assets
(0.40)
Return On Equity
(0.91)
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Inovio Pharmaceuticals Cash Per Share vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Inovio Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Inovio Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Inovio Pharmaceuticals is rated fourth overall in current valuation category among its peers. It is rated below average in cash per share category among its peers . The ratio of Current Valuation to Cash Per Share for Inovio Pharmaceuticals is about  24,191,096 . At this time, Inovio Pharmaceuticals' Cash Per Share is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Inovio Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Inovio Current Valuation vs. Competition

Inovio Pharmaceuticals is rated fourth overall in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 764.5 Million. Inovio Pharmaceuticals holds roughly 33.87 Million in current valuation claiming about 4% of equities under Health Care industry.

Inovio Cash Per Share vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Inovio Pharmaceuticals

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
33.87 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Inovio Pharmaceuticals

Cash Per Share

 = 

Total Cash

Average Shares

 = 
1.40 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.

Inovio Cash Per Share Comparison

Inovio Pharmaceuticals is currently under evaluation in cash per share category among its peers.

Inovio Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Inovio Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Inovio Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Inovio Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Inovio Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-662.6 K-629.5 K
Operating Income-135.2 M-128.5 M
Income Before Tax-135.1 M-128.4 M
Total Other Income Expense Net109.3 K114.8 K
Net Loss-135.1 M-128.4 M
Income Tax Expense 2.00  1.90 
Net Loss-164.6 M-172.8 M
Non Operating Income Net Other-1.1 M-1.2 M
Net Loss-251.8 M-239.2 M
Interest Income8.2 M8.6 M
Net Interest Income6.9 M7.3 M
Change To Netincome34.5 M20.1 M
Net Loss(6.09)(6.40)
Income Quality 0.92  0.87 
Net Income Per E B T 1.19  1.13 

Inovio Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Inovio Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Inovio Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Inovio Pharmaceuticals' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Inovio Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Sign In To Macroaxis Now

   

Sign In To Macroaxis

Sign in to explore Macroaxis' wealth optimization platform and fintech modules
All  Next Launch Module

Use Investing Themes to Complement your Inovio Pharmaceuticals position

In addition to having Inovio Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Precious Metals ETFs Thematic Idea Now

Precious Metals ETFs
Precious Metals ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Precious Metals ETFs theme has 28 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Inovio Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inovio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inovio Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inovio Pharmaceuticals Stock:
Check out Risk vs Return Analysis.
To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
To fully project Inovio Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Inovio Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Inovio Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Inovio Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Inovio Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Inovio Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Inovio Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.